Abattis Announces the Appointment of Dr. Shuang Xie as a Director and Provides Progress Report on Initiatives in China
Vancouver, British Columbia--(Newsfile Corp. - November 14, 2016) - Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), is pleased to announce the appointment of Dr. Shuang Xie to the Board of Directors. Dr. Xie recently joined Abattis as the Chief Technology Advisor and continues in that capacity. Abattis is also pleased provide an update on its initiatives in China.Our new director, Dr. Shuang Xie has been diligently working in China to increase the profile of...
2016-11-14 8:26 AM EST
Abattis Announces Licensing Deal and Brand Acquisition Between Vergence and Green Nature Health Care Products Inc., of China
Vancouver, British Columbia--(Newsfile Corp. - November 9, 2016) - Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), announces that the Company and its subsidiary, Vergence Visionary Bioceuticals Corp. doing business as Vergence Sales and Marketing Group, have entered into an international licensing and co-branding agreement with Green Nature Health Care Products Inc. ("Green Nature") of mainland China. Under the terms of the Licensing Agreement Abattis may...
2016-11-09 8:39 AM EST
Abattis Announces Renewal of Health Canada Licence
Vancouver, British Columbia--(Newsfile Corp. - November 7, 2016) - Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), announces the renewal of the Health Canada Licence for the Northern Vine Canada Inc. testing lab. Health Canada has confirmed the renewal of the Langley, BC facility's controlled substances testing licence. The Company has fulfilled Health Canada's rigorous specifications, and successfully completed all thorough inspections. Accordingly, the lab...
2016-11-07 8:15 AM EST
Abattis Announces the Appointment of New Independent Director
Vancouver, British Columbia--(Newsfile Corp. - November 2, 2016) - Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), announces the appointment of Dr. William Panenka to the Board of Directors.Dr. Panenka received his M.D. and M.Sc. from the University of Calgary in Canada. His M.Sc was basic science-focused utilizing Western Blotting, PCR, in-situ hybridization and other wet lab techniques. He completed residencies in both psychiatry and neurology at the...
2016-11-02 9:47 AM EDT
Abattis Executes Memorandum of Agreement to Acquire 100% of Experion Biotechnologies Inc.
Vancouver, British Columbia--(Newsfile Corp. - October 24, 2016) - Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), announces that Abattis and Northern Vine have entered into a Binding Memorandum of Agreement with Experion Biotechnologies to acquire up to 100% of Experion Biotechnologies Inc.Abattis Bioceuticals Corp., and its subsidiary Northern Vine Canada Inc., expect to advance up to $5 million in the near term and $2.5 million in deferred capital to...
2016-10-24 8:37 AM EDT
Abattis Issues Common Shares
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2016) - Abattis Bioceuticals Corp. (OTCQX: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), announces that today the Company issued 1,270,157 common shares as compensation for services to consultants, directors and employees of the Company for the month ended September 30, 2016 and in respect of prior months outstanding, no legend was required on any of the issued shares. About Abattis Bioceuticals Corp. Abattis is a specialty...
2016-10-21 8:11 PM EDT
Abattis Bioceuticals Corp.: Experion Biotechnologies Prepares for Construction
Vancouver, British Columbia--(Newsfile Corp. - October 17, 2016) - Abattis Bioceuticals Corp. (OTCQX: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), announces commencement of construction for the Experion secure, production facility.Experion Biotechnologies Inc. is pleased to announce that it has begun the construction process and prepares to break ground for the six-month build-out for its 8,000 square foot, phase one facility. This first phase will provide the operational infrastructure...
2016-10-17 8:42 AM EDT
Abattis Signs MOU with Global Damon Pharma of South Korea
Vancouver, British Columbia--(Newsfile Corp. - October 5, 2016) - Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis") is pleased to announce that it has entered into a Memorandum of Understanding with Global Damon Pharma ("GDP") of South Korea, to distribute and sell Abattis' proprietary PhytoNOS™ and Sassy™ Tonics in modified formulations. GDP will engage in the research and creation of necessary components for completion of these two products and will negotiate...
2016-10-05 8:30 AM EDT
Abattis' Northern Vine Labs Receives Controlled Substance Licence
Vancouver, British Columbia--(Newsfile Corp. - October 3, 2016) - Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), is pleased to announce that Northern Vine has received a letter from Health Canada and a copy of the licence informing that it is now an authorized Licensed Dealer."We wish to congratulate the Northern Vine team on this important milestone for the Company. We have remained patient in obtaining this licence. We persevered and were granted Licence...
2016-10-03 8:47 AM EDT
Update: New Science Advisor and Comptroller Appointment to Abattis
Vancouver, British Columbia--(Newsfile Corp. - September 27, 2016) - Abattis Bioceuticals Corp. (OTCQX: ATTBF) (CSE: ATT) (the "Company" or "Abattis") is pleased to announce the appointment of Dr. Shuang Xie as its newest Science and Technology Advisor. Dr. Xie graduated from Zhejiang University in 1987 and Queen's University in 1993. Dr. Xie has been widely published and holds more than 20 patents. She has assisted companies globally in assessing project risk, securing financing, and has...
2016-09-27 8:59 AM EDT
Abattis Issues Common Shares
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2016) - Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), announces that today the Company issued 3,303,076 common shares as compensation for services to consultants, directors and employees of the Company for the month ended August 31, 2016 and in respect of prior months outstanding, no legend was required on any of the issued shares. The Company also announced that it has agreed to issued 1,040,945...
2016-09-22 10:45 PM EDT
Abattis Amends Certain Warrants
Vancouver, British Columbia--(Newsfile Corp. - September 12, 2016) - Abattis Bioceuticals Corp. (OTCQX: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), announces that today the Company is repricing certain warrants issued pursuant to a private placement on March 17, 2015. The Company will amend the following terms: Original TermsRevi
2016-09-12 4:05 PM EDT
Abattis Issues Common Shares, Obtains a Credit Facility and a Change in the Board
Vancouver, British Columbia--(Newsfile Corp. - August 12, 2016) - Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), announces that today the Company issued 2,621,452 common shares as compensation for services to consultants, directors and employees of the Company for the month ended July 31, 2016, no legend was required on any of the issued shares.The Company is saddened to announce the untimely death of one of its directors, Tim Fealey. Mr. Fealey joined the...
2016-08-12 9:21 PM EDT
Abattis Announces a New Distribution Agreement and Change in Officers
Vancouver, British Columbia--(Newsfile Corp. - August 10, 2016) - Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), is pleased to announce that it has entered into an exclusive distribution agreement with the Jiangsu Regent Granary Trading Co., Ltd. ("Jaingsu"). Jaingsu is one of a select few that is exporting Canadian beef to China. They also export granola, dried fruit and will also include Abattis' line of Phytnos Superfruit tonics and VitaGum in mainland...
2016-08-10 5:23 PM EDT
Abattis Announces Co-Formulation with Vitagum(TM)
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2016) - Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB : ATTBF) ("Abattis") through its proposed licensing arrangement with Crimson Capital Group ("Crimson") is pleased to announce that a letter of intent to co-formulate gum products under the brand name VitagumTM has now been signed.Once the arrangement has been approved by the Canadian Stock Exchange (the "CSE"), Abattis and Crimson will finalize plans to co- formulate new gum products...
2016-04-18 8:00 AM EDT
Abattis Receives NPN from Health Canada for Phyto(NOS)(TM)
Vancouver, British Columbia--(Newsfile Corp. - April 12, 2016) - Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) ("Abattis") is pleased to announce that it has received a Natural Product Number ("NPN") approval for Phyto(NOS)TM. This NPN allows Abattis to manufacture and to sell Phyto(NOS) TM in Canada. Ingredient Identity of Santa Ana, California, completed the claim substantiation report necessary for the sale of Phyto(NOS)TM in the United States. Phyto(NOS)TM is an all-natural,...
2016-04-12 8:00 AM EDT
Abattis Agrees to License Its NOXX Botanical Blends Products
Vancouver, British Columbia--(Newsfile Corp. - April 6, 2016) - Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) ("Abattis') has agreed to enter a licensing arrangement and marketing partnership with Crimson Capital Group ("Crimson") to commercialize Abattis' NÖXX Botanical Blends Products, which contain Abattis' patent-pending Phyto(NOS)™.Abattis and Crimson plan to enter into an exclusive licensing agreement within thirty days, subject to all necessary approvals. "We are extremely...
2016-04-06 10:51 AM EDT
Abattis Subsidiary, Vergence, Announces First Product in Lineup Now Available for Sale
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2016) - Vergence Sales and Marketing Group, wholly owned subsidiary of Abattis Bioceuticals Corp. (OTCQX: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), is pleased to announce the launch and sale of NÖXX BOTANICAL BLENDS™. Each NÖXX product contains PHYTO[NOS]™, a proprietary nitric oxide formula, blended with specific natural fruit and herb extracts that promotes vascular function, immune system function, sexual function and works in...
2016-03-03 9:00 AM EST